JAGUAR HEALTH, INC. Noncontrolling Interest, Increase from Subsidiary Equity Issuance
JAGUAR HEALTH, INC. (JAGX) reported Noncontrolling Interest, Increase from Subsidiary Equity Issuance of $1.23 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Shareholders' Equity › Noncontrolling Interest Items
us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance · last filed 2025-03-31
- JAGUAR HEALTH, INC. noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2023-12-31 was $0.00.
- JAGUAR HEALTH, INC. noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2023-09-30 was $1.00K.
- JAGUAR HEALTH, INC. noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2023-06-30 was $0.00.
- JAGUAR HEALTH, INC. noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2023-03-31 was $1.23M.
- JAGUAR HEALTH, INC. noncontrolling interest, increase from subsidiary equity issuance for fiscal 2023 was $1.23M.
| Period end | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 3 month | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 6 month | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 9 month | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.00K derived: sum of 3 quarters · filed 2025-03-31 | $1.23M 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.00K derived: sum of 2 quarters · filed 2024-11-13 | $1.23M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.23M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $1.23M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |